Skip to main content
. Author manuscript; available in PMC: 2011 Mar 15.
Published in final edited form as: J Immunol. 2010 Feb 17;184(6):3250–3259. doi: 10.4049/jimmunol.0900722

Figure 1.

Figure 1

(A) No evidence of HSV-1 or HSV-2 seroconversion in IS subjects. Sera drawn on study entry, day 0 (d0), or during the course of study from IS3, IS12 and IS19 were analyzed for the presence of antibodies to HSV-1 (1) and HSV-2 (2) by WB. Controls included sera from HSV-1+ (HSV-1), HSV-2+ (HSV-2), HSV-1+/2+ (HSV-1/2) and HSVneg (neg) subjects. (B) Response rates of IS and non-IS subjects to HSV-2 and control peptide pools. PBMC from 20 IS and 46 non-IS subjects were screened for IFN-γ ELISPOT responses using peptide pools from CMV, CEF, or 34 pools of overlapping peptides representing 16 different HSV-2 ORFs (Table I). The % of subjects with positive responses to the different antigens is displayed; for CMV responses, only CMV-seropositive subjects were included (n=6 for IS subjects and n=6 for non-IS subjects). (C) Breadth of HSV-2 peptide pool response in IS and HSV-2+ subjects. The percentage of IS subjects (n=20) or HSV-2+ subjects (n=40) who responded to 0-12 different HSV-2 peptide pools is displayed. (D) Diversity of HSV-2 peptide-specific responses in IS subjects. The response rates of IS subjects (n=20) to individual HSV-2 proteins is displayed. (E) Diversity of HSV-2 peptide-specific responses in HSV-2+ subjects. The response rates of HSV-2+ subjects (n=40) to individual HSV-2 proteins is displayed. *Peptide pools recognized more frequently in HSV-2+ subjects compared to IS subjects.